Traditional pharma marketing, heavily reliant on science and data, can be improved by adopting consumer goods principles. This involves focusing on simplicity, message consistency, and tapping into emotional insights to cut through a cluttered and competitive marketplace.

The iconic name 'Viagra' was created for a prostate drug to evoke a "vigorous stream." When Pfizer developed a drug for erectile dysfunction, it repurposed the pre-existing, "banked" name, showing how companies strategically reuse branding assets for a better fit.

Regulators cracked down on Hims not solely for selling compounded GLP-1s, but because of a confluence of provocative actions. A highly visible Super Bowl ad and a bold oral pill launch created a perception of 'thumbing the nose' at regulators and Novo Nordisk, forcing a decisive response.

Atorvastatin's market dominance was driven by a pivotal 1997 FDA rule change allowing direct-to-consumer ads. Pfizer's marketing team treated the drug not as a medical compound, but as a consumer product like Nike, creating massive patient-led demand.

Adderall's success proves a core chemical patent isn't essential for market dominance. A strong brand that becomes synonymous with a condition, combined with secondary patents on novel delivery mechanisms (like Adderall XR's capsule), can create a durable, highly profitable business moat.

Pharmaceutical marketing can be transformed by adopting principles from consumer goods giants like Unilever. This involves focusing on simplicity, messaging consistency, and leveraging emotional customer insights, moving beyond a purely science-driven approach to cut through market clutter and build a stronger brand.

SAS found its well-oiled demand generation marketing was hitting a ceiling of effectiveness. Investing in brand advertising was not just a long-term strategy but a necessary intervention to unlock further short-term growth. The brand halo effect increased the efficiency of all their performance channels, breaking the plateau.

An executive order mandated lengthy risk disclosures in pharmaceutical TV ads, reducing their effectiveness and ROI. This regulatory change made traditional consumer advertising less attractive, accelerating the shift of billions in pharma marketing spend toward more efficient digital channels like Doximity.

Bonafide Health expanded into Target and Amazon first ("physical availability") but found it's a "hard sell" if shoppers don't recognize the brand. They are now using TV to build brand recognition ("mental availability") to support their retail presence, reversing the traditional brand-first approach.